✦ LIBER ✦

Primary and locally recurrent retroperitoneal soft-tissue sarcoma: Local control and survival

✍ Scribed by T. Lehnert; S. Cardona; U. Hinz; F. Willeke; G. Mechtersheimer; M. Treiber; C. Herfarth; M.W. Buechler; M.H.M. Schwarzbach

Book ID: 116443460
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 239 KB
Volume: 35
Category: Article
ISSN: 0748-7983
DOI: 10.1016/j.ejso.2008.11.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Local recurrence and survival in soft-ti

Local recurrence and survival in soft-tissue sarcomas

✍ Constantine P. Karakousis; C. Proimakis; Uma Rao; Augustine F. Velez; Deborah L. 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 497 KB

Primary and recurrent retroperitoneal so

Primary and recurrent retroperitoneal soft tissue sarcoma: Prognostic factors affecting survival

✍ Antonio Chiappa; Andrew P. Zbar; Emilio Bertani; Roberto Biffi; Fabrizio Luca; C 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

Survival after local recurrence of soft

Survival after local recurrence of soft tissue sarcoma

✍ R. A. Evans 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 2 views

Erratum: Primary and recurrent retroperi

Erratum: Primary and recurrent retroperitoneal soft tissue sarcoma: Prognostic factors affecting survival

✍ Antonio Chiappa; Andrew P. Zbar; Emilio Bertani; Roberto Biffi; Fabrizio Luca; C 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB

Combination of primary and recurrent tum

Combination of primary and recurrent tumor characteristics predict survival in locally recurrent extremity soft tissue sarcoma

✍ F. C. Eilber; M. F. Brennan; K. Alektiar; E. Riedel; S. Singer 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 185 KB

Treatment and local control of primary e

Treatment and local control of primary extremity soft tissue sarcomas

✍ Karakousis, Constantine P.; Driscoll, Deborah L. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

Background and Objectives: Modern series of adult extremity soft tissue sarcomas utilize combinations of modalities in all patients. Remaining questions: 1) is it necessary to strive for wide margins in the multimodality era; 2) to use adjuvant therapy in every high-grade sarcoma? 3) Does previous p